



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





PREVALENCE OF ABNORMAL LIVER FUNCTIONS IN COVID-19 PATIENTS

Thesis

Submitted for Partial Fulfillment of Master Degree
In Internal Medicine

By

Hagar Fawzy Fahmey

M.B.B.CH

Internal Medicine Department,
Ain Shams University

Supervised by

Prof. Noha Abdelrazek Elnakeeb

Professor of Hepatology and Gastroenterology
Faculty of Medicine - Ain Shams University

Prof. Mohamed Magdy Mohamed Ibrahim

Professor of Hepatology and Gastroenterology
Faculty of Medicine - Ain shams University

Dr. Hagar Ahmed Ahmed Elissaway

Lecture of Hepatology and Gastroenterology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University

2022



مدي انتشار وظائف الكبد الغير طبيعيه لدي مرضي كوفيد-١٩

رسالة

توطئة للحصول على درجة الماجستير
فى الباطنة العامة

مقدمة من

الطبيبة / هاجر فوزي فهمي
بكالوريوس الطب والجراحة العامة
كلية الطب – جامعة عين شمس

تحت اشراف

أ.د/ نهى عبد الرازق النقيب
أستاذ الكبد والجهاز الهضمي
كلية الطب - جامعة عين شمس

أ.د/ محمد مجدي محمد ابراهيم
أستاذ الكبد والجهاز الهضمي
كلية الطب - جامعة عين شمس

د/ هاجر احمد احمد العيسوي
مدرس الكبد والجهاز الهضمي
كلية الطب - جامعة عين شمس

كلية الطب
جامعة عين شمس
٢٠٢٢

List of Contents

Title	Page
▪ List of Abbreviations.....	I
▪ List of Tables.....	III
▪ List of Figures	V
▪ Introduction.....	1
▪ Aim of the Study	3
▪ Review of Literature	
- Chapter (1): Liver Injury	4
- Chapter (2): COVID-19 Patients.....	31
- Chapter (3): Pattern of Liver Injury in COVID-19 Patients.....	54
▪ Patients and Methods	71
▪ Results	78
▪ Discussion	106
▪ Conclusion	117
▪ Recommendations	118
▪ Summary.....	119
▪ References.....	124
▪ Arabic Summary.....	--

List of Abbreviations

Abb.	Full term
2019-nCoV	2019 New Corona Virus
AAT	Alpha-1-Antitrypsin Deficiency
AAT	α 1 -Antitrypsin
ACE2	Angiotensin-Converting Enzyme 2
ACLF	Acute-on-Chronic Liver Failure
ALP	Alkaline Phosphatase
ALT	Alanine Transaminase
ALT	Alanine Aminotransferase
ARDS	Acute Respiratory Distress Syndrome
AST	Aspartate Aminotransferase
CMV	Cytomegalovirus
CoV	Corona Virus
COVID-19	Corona Virus Disease 2019
CRP	C-Reactive Protein
CRS	Cytokine Release Syndrome
CSF	Colony-Stimulating Factor
CT	Computed Tomography
CYP 3A4	Cytochrome P450
DILI	Drug Induced Liver Injury
DILI	Drug-Induced Liver Damage
EUA	Emergency Use Authorization
FNH	Focal Nodular Hyperplasia
FXR	Farnesoid X Receptor
GGT	Gamma Glutamyl Transferase
GM	Granulocyte-Macrophage
HS	Highly Significant

List of Abbreviations (Continued)

Abb.	Full term
ICU	Intensive Care Unit
IP-10	Interferon- γ Inducible Protein 10
LAMP	Loop-Mediated Isothermal Amplification
LDH	Lactate Dehydrogenase
MCP-1	Monocyte Chemoattractant Protein 1
MERS	Middle East Respiratory Syndrome
MIP-1α	Macrophage Inflammatory Protein 1- α
NASH	Non-Alcoholic Steatohepatitis-Related Liver Fibrosis
NS	Non Significant
PBC	Primary Biliary Cirrhosis
PCR	Polymerase Chain Reaction
P-gp	P-glycoprotein
PSC	Primary Sclerosing Cholangitis
RAS	renin-angiotensin system
RR	Respiration Rate
rRT	Real-Time Reverse Transcription
RT	Reverse Transcription
S	Significant
SARS	Severe Acute Respiratory Syndrome
SARS-CoV-2	Severe Acute Respiratory Syndrome Corona Virus 2
TBIL	Total Bilirubin
TMA	Transcription-Mediated Amplification
TNF-α	Tumour Necrosis Factor- α
ULN	Upper Limit Unit of Normal
WHO	World Health Organization

List of Tables

Table No.	Title	Page
Review of Literature		
Table (1):	Minor nonspecific changes in liver biopsies.....	6
Results		
Table (1):	Comparison between moderate and severe group regarding age, sex, disease duration and hospital stay	78
Table (2):	Comparison between studied groups regarding comorbidities	82
Table (3):	Comparison between moderate and severe group regarding COVID-19 symptoms at admission.....	84
Table (4):	Comparison between studied groups regarding clinical examination (respiratory rate and oxygen saturation)	86
Table (5):	Comparison between studied groups as regard CBC at admission	88
Table (6):	Comparison studied groups regarding CRP, ferritin and D-Dimer....	90
Table (7):	Comparison between studied groups regarding CT chest finding at admission	92
Table (8):	Incidence of elevated AST, ALT, bilirubin at admission	94

List of Tables (Continued)

Table No.	Title	Page
Table (9):	Correlation between dyspnea and AST, ALT, bilirubin at time of admission	95
Table (10):	Correlation between AST, ALT, bilirubin and respiratory rate and oxygen saturation.....	95
Table (11):	Correlation between AST, ALT, bilirubin and laboratory finding regard TLC, ferritin and D-dimer	98
Table (12):	Comparison between studied groups regarding AST, on admission, during hospital stay and discharge and dynamic changes of it along course of disease	100
Table (13):	Comparison between studied groups regarding ALT, on admission, during hospital stay and discharge and dynamic changes of it along course of disease	102
Table (14):	Comparison between studied group regarding bilirubin, on admission, during hospital stay and discharge and dynamic changes of it along course of disease	104

List of Figures

Figure No.	Title	Page
Review of Literature		
Fig. (1):	Acute hepatocyte injury.....	11
Fig. (2):	Evaluation of hepatic inflammation	12
Fig. (3):	Three forms of necrosis. (a) Centrilobular, (b) Midzonal and (c) Periportal	17
Fig. (4):	Multiple organ injuries in SARS- CoV-2 infection	40
Fig. (5):	COVID-19 can cause direct liver damage, either through ACE-2 entry or indirect through generalized inflammation caused by the cytokine cascade	61
Results		
Fig. (1):	Comparison between the studied groups as regard age ($P > 0.189$).....	80
Fig. (2):	Comparison between the studied groups as regard sex ($P = 0.001$)	80
Fig. (3):	Comparison between studied groups as regard disease duration ($P < 0.001$) ..	81
Fig. (4):	Comparison between studied group as regard hospital stay ($P < 0.001$)	81
Fig. (5):	Comparison between studied groups as regard co-morbidities	83
Fig. (6):	Comparison between studied groups regarding COVID symptoms at admission	85

List of Figures (Continued)

Figure No.	Title	Page
Fig. (7):	Comparison between studied groups regard RR at admission	87
Fig. (8):	Comparison between studied groups oxygen saturation at admission	87
Fig. (9):	Comparison between studied groups regard TLC at admission	89
Fig. (10):	Comparison between studied groups as regard ferritin at admission.....	91
Fig. (11):	Comparison between studied groups as regard D-dimer at admission.....	91
Fig. (12):	Comparison between studied groups regarding CT finding at admission	93
Fig. (13):	Incidence of elevated AST, ALT, Bilirubin in total patient through admission	94
Fig. (14):	Correlation between AST and respiratory rate at admission.....	96
Fig. (15):	Correlation between ALT and respiratory rate at admission.....	96
Fig. (16):	Correlation between bilirubin and respiratory rate at admission.....	97
Fig. (17):	Correlation between ALT and ferritin level at admission.....	98
Fig. (18):	Correlation between AST and ferritin level at admission.....	99

List of Figures (Continued)

Figure No.	Title	Page
Fig. (19):	Comparison between studied groups regard AST along course of the disease.....	101
Fig. (20):	Comparison between studied group regard median of AST along course of disease	101
Fig. (21):	Comparison between studied groups regarding ALT along course of disease.....	103
Fig. (22):	Comparison of studied groups regarding median of ALT along course of disease.....	103
Fig. (23):	Comparison between studied groups regarding bilirubin along course of disease.....	105
Fig. (24):	Comparison between studied groups regarding median of BILIRUBIN along course of disease.....	105

INTRODUCTION

Corona viruses are a family of viruses that are known to cause both respiratory and intestinal diseases in Various animal species and humans (*Dong et al., 2019*). These viruses tend to target the upper respiratory tract, causing Anywhere from moderate to severe illnesses, such as the cold or in more extreme cases, pneumonia. To date, 7 human corona viruses have been identified, including the 3 epidemic viruses of severe acute respiratory syndrome (SARS)-CoV, middle east respiratory syndrome (MERS)-CoV and the newest, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) (*Niu et al., 2016*).

In December of 2019, a series of pneumonia cases of unknown origin began to spread in the central city of Wuhan, China. Now identified as SARS-CoV-2, the virus had gone on to infect more than 300,000 people Worldwide by March 2020 (*Jia et al., 2019*).

The corona virus disease (COVID-19) has been labelled a pandemic by the World Health Organization (WHO) having led to thousands of deaths and hospitalizations worldwide.

While most COVID-19 cases have been identified as mild, more extreme diagnoses have led to respiratory failure, septic shock, and/or multiple organ dysfunction (*Wu and McGoogan, 2020*).

-Introduction-

In symptomatic patients, the clinical manifestations of the disease usually present as fever, cough, fatigue and other signs of respiratory tract infections (***Chen et al., 2020; Wang et al., 2020***). In severe cases, individuals elicit symptoms of pneumonia with abnormal chest CT, associated with complications of severe acute respiratory distress. Syndrome, acute cardiac injury, kidney failure, and eventually death.

Liver impairment has been reported as a common clinical manifestation in patients with SARS-COV infection, even if not a prominent feature of the illness (***Humar et al., 2004; Chan et al., 2004***). In the novel epidemic SARS-CoV-2, it is still unclear how significant liver impairment is. In the present study, we sought to analyse liver function changes (AST, ALT, Bilirubin, ALBUMIN) and evaluate its relationship with the disease progression in COVID-19 patients.

AIM OF THE STUDY

To evaluate the incidence of concurrent elevation of liver function tests (AST, ALT, Bilirubin), decrease albumin, examine dynamic changes of it and its relationship with disease throughout the course of COVID-19 patients.

CHAPTER (1): COVID-19 THE NOVEL VIRUS

Corona virus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic (*Vaira et al., 2020*).

Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Of those people who develop noticeable symptoms, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are more likely to have severe symptoms. At least a third of the people who are infected with the virus remain asymptomatic and do not develop noticeable symptoms at any point in time, but they still can spread the disease. Around 20% of those people will remain asymptomatic throughout infection, and the rest will develop symptoms later on, becoming pre symptomatic rather than asymptomatic and therefore having a higher risk of transmitting the virus to others. Some people continue to